FDA Grants Atia Vision Approval to begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts

CAMPBELL, CA – May 20, 2025 – Atia Vision, Inc., a Shifamed portfolio company, today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a traditional feasibility clinical study of its OmniVu™ Lens System. This novel intraocular lens is designed to restore dynamic range of vision following cataract surgery, going beyond the capabilities of current presbyopia-correcting lenses.

Read More >

FDA Grants Atia Vision Approval to begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts2025-05-20T10:29:46-07:00

Atia Vision Announces Presentation of First-In-Human Results with Their Novel Intraocular Lens at American Society of Cataract Refractive Surgery (ASCRS) Annual Meeting

CAMPBELL, CA – May 5, 2023 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular shape-changing intraocular lens (IOL), today announced the first clinical data about their patented OmniVu™ IOL System will be presented at the 2023 Annual Meeting of the American Society of Cataract Refractive Surgery (ASCRS) in San Diego, California.

Read More >

Atia Vision Announces Presentation of First-In-Human Results with Their Novel Intraocular Lens at American Society of Cataract Refractive Surgery (ASCRS) Annual Meeting2023-05-05T06:56:14-07:00

Atia Vision, a Shifamed Portfolio Company, to Close on $42m Series E Financing

CAMPBELL, CA – August 2, 2022 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting intraocular lens (IOL), announced today the first close of a $42M Series E financing. Led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), PA MedTech VC Fund, AMED Ventures and Shifamed angel investors, funds will be used to expand the company’s clinical program, scale its manufacturing capabilities, and expand the Atia Vision team.

Read More >

Atia Vision, a Shifamed Portfolio Company, to Close on $42m Series E Financing2023-04-28T16:26:58-07:00

Atia Vision Closes Second Tranche of $20M in Series D Financing

CAMPBELL, CA – May 2, 2020 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.

Read More >

Atia Vision Closes Second Tranche of $20M in Series D Financing2022-07-20T13:31:49-07:00

Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting Intraocular Lens Technology

CAMPBELL, CA – September 11, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a novel modular presbyopiacorrecting intraocular lens (IOL), today announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France.

Read More >

Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting Intraocular Lens Technology2019-09-12T10:28:10-07:00

Atia Vision, A Shifamed Portfolio Company, Closes $20M in Series D Financing

CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.

Read More >

Atia Vision, A Shifamed Portfolio Company, Closes $20M in Series D Financing2019-09-12T10:28:41-07:00

Atia Vision, A Shifamed Portfolio Company, Closes $10m In Series C Financing

CAMPBELL, CA – December 10, 2018 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular accommodating intraocular lens, announced today the closing of its second tranche of a Series C preferred stock financing, raising a total of $10M. Atia Vision’s unique technology enables natural accommodation, utilizing the ciliary muscles of the eye and providing for subsequent refractive correction, to restore the full range of functional vision for cataract patients. Led by The Capital Partnership (TCP), with participation from Medvance Incubator Partners and Cormorant Healthcare Fund, the financing officially closed on November 9, 2018. The funds raised in this round will support Atia Vision’s clinical efforts.

Read More >

Atia Vision, A Shifamed Portfolio Company, Closes $10m In Series C Financing2019-03-13T09:23:08-07:00

Atia Vision Closure of $4M in Series C Financing

CAMPBELL, CA – May 8, 2017 – Atia Vision, a privately held medical device company focused on developing an accommodating intraocular lens to address the unmet clinical needs in the intraocular market, today announced it has closed $4M in the first tranche of its Series C financing.

Atia Vision Closure of $4M in Series C Financing2019-03-13T09:23:46-07:00
Go to Top